As an important part of epigenomics, DNA methylation is involved in processes such as cell and tissue differentiation, development, aging, and environmental adaptation. Changes in DNA methylation patterns are related to multiple diseases, including cancer, mental disorders, diabetes, and cardiovascular disease (CVD). Based on the Illumina chip, CapitalBio Technology offers a comprehensive solution for DNA methylation detection and analysis, providing a one-stop service that covers screening and verification.
As an economic and efficient DNA methylation analysis high-throughput screening technology platform, the Illumina 850K methylation array can precisely detect methylation variations at the single-base level. This chip is a powerful tool for researching complex diseases such as tumors, respiratory system disorders, CVD, and mental diseases. It also serves as a high-throughput detection technology platform applicable to Epigenome-Wide Association Studies (EWAS).
CapitalBio Technology also offers methylation sequencing, methylation analysis, DNA methylation tests, and genetic methylation testing to support a wide range of research needs.